Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Jacques Medioni"'
Autor:
Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, Lise Boussemart, Jean Chiesa, Clotilde Deldycke, Carlos Gomez-Rocca, Antoine Hollebecque, Jacqueline Lehmann-Che, Antoinette Lemoine, Sandrine Mansard, Jacques Medioni, Isabelle Monnet, Samia Mourah, Thomas Pierret, Dominique Spaëth, Alexandre Civet, Sandrine Galoin, Antoine Italiano
Publikováno v:
PLoS ONE, Vol 18, Iss 9, p e0291495 (2023)
IntroductionConsidering the growing interest in matched cancer treatment, our aim was to evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least one targeted therapy given an identified genomic alteration or signatur
Externí odkaz:
https://doaj.org/article/8bec3a2beb214f7a869dd1f1edcdeb6c
Autor:
Maud Velev, Alicja Puszkiel, Benoit Blanchet, Sixtine de Percin, Nicolas Delanoy, Jacques Medioni, Claire Gervais, David Balakirouchenane, Nihel Khoudour, Patricia Pautier, Alexandra Leary, Zahra Ajgal, Laure Hirsch, François Goldwasser, Jerome Alexandre, Guillaume Beinse
Publikováno v:
Pharmaceuticals, Vol 14, Iss 8, p 804 (2021)
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed to retrospectiv
Externí odkaz:
https://doaj.org/article/58923e84ca98466e86ca7b10c494bf84
Publikováno v:
Contemporary Clinical Trials Communications, Vol 7, Iss , Pp 186-188 (2017)
Introduction: Crotoxin has a broad antitumor activity but has shown frequent neurotoxic toxicity. To induce tolerance and limit this toxicity, we propose a new design with intra-patient dose escalation. Methods: A new Dose Limiting Toxicity definitio
Externí odkaz:
https://doaj.org/article/11519776c03a48f78a14cdffc55318b0
Autor:
Jacques Medioni, Daniel Scimeca, Yecenia Lopez Marquez, Emmanuelle Leray, Marie Dalichampt, Nicolas Hoertel, Mohammed Bennani, Pascal Trempat, Naoual Boujedaini
Publikováno v:
Clinical Breast Cancer
Clinical Breast Cancer, 2022, ⟨10.1016/j.clbc.2022.10.001⟩
Clinical Breast Cancer, 2022, ⟨10.1016/j.clbc.2022.10.001⟩
International audience; BackgroundComplementary therapy in oncology aims to help patients better cope with the illness and side effects (SEs) of cancer treatments that affect their quality of life (QOL). This study aimed to assess the benefits of hom
Autor:
Pierre Langlade-Demoyen, Thierry Huet, Valérie Doppler, Simon Wain-Hobson, Stephane Oudard, Stephane Culine, Rémy Defrance, Marie Escande, Elodie Pliquet, Maria Wehbe, Caroline Laheurte, Mara Brizard, Jean-Jacques Kiladjian, Zineb Ghrieb, Marie-Agnès Dragon Durey, Ludovic Doucet, Olivier Adotevi, Julie Garibal, Jacques Medioni, Luis Teixeira
Purpose:Human telomerase reverse transcriptase (hTERT) is highly expressed in >85% of human tumors and is thus considered as a good tumor-associated antigen candidate for vaccine development. We conducted a phase I study to investigate the safety, to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd906c2cdab8e76b1aca5f20a7b6425
https://doi.org/10.1158/1078-0432.c.6528819
https://doi.org/10.1158/1078-0432.c.6528819
Autor:
Eric Tartour, Ludger Johannes, Stephane Oudard, Jacques Medioni, Luis CS Ferreira, Craig Sibley, Sylvie Godefroy, Yu Chun Lone, Nathalie Merillon, Alain Gey, Estelle Dransart, Mariana O. Diniz, Thi Tran
Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer. In this study, we aimed to optimize the E75 vaccine using a delivery vector targeting dendritic cells, the B-subunit of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142594a69bd5086f91adf2070b71b16a
https://doi.org/10.1158/1078-0432.c.6525336
https://doi.org/10.1158/1078-0432.c.6525336
Autor:
Pierre Langlade-Demoyen, Thierry Huet, Valérie Doppler, Simon Wain-Hobson, Stephane Oudard, Stephane Culine, Rémy Defrance, Marie Escande, Elodie Pliquet, Maria Wehbe, Caroline Laheurte, Mara Brizard, Jean-Jacques Kiladjian, Zineb Ghrieb, Marie-Agnès Dragon Durey, Ludovic Doucet, Olivier Adotevi, Julie Garibal, Jacques Medioni, Luis Teixeira
Histological diagnosis, age, number of cycles received and Overall Survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc139436bbee1039bc86333868c1abc
https://doi.org/10.1158/1078-0432.22474542.v1
https://doi.org/10.1158/1078-0432.22474542.v1
Autor:
Pierre Langlade-Demoyen, Thierry Huet, Valérie Doppler, Simon Wain-Hobson, Stephane Oudard, Stephane Culine, Rémy Defrance, Marie Escande, Elodie Pliquet, Maria Wehbe, Caroline Laheurte, Mara Brizard, Jean-Jacques Kiladjian, Zineb Ghrieb, Marie-Agnès Dragon Durey, Ludovic Doucet, Olivier Adotevi, Julie Garibal, Jacques Medioni, Luis Teixeira
Immunophenotyping of circulating CD4 and CD8 T cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545f629222aeb2e02a1547eecf49b3b8
https://doi.org/10.1158/1078-0432.22474548
https://doi.org/10.1158/1078-0432.22474548
Autor:
Pierre Langlade-Demoyen, Thierry Huet, Valérie Doppler, Simon Wain-Hobson, Stephane Oudard, Stephane Culine, Rémy Defrance, Marie Escande, Elodie Pliquet, Maria Wehbe, Caroline Laheurte, Mara Brizard, Jean-Jacques Kiladjian, Zineb Ghrieb, Marie-Agnès Dragon Durey, Ludovic Doucet, Olivier Adotevi, Julie Garibal, Jacques Medioni, Luis Teixeira
Number and percentage of patients reporting studytreatment-related AEs per cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1bff112bdd3efd6d804d56003e8137
https://doi.org/10.1158/1078-0432.22474539.v1
https://doi.org/10.1158/1078-0432.22474539.v1
Autor:
Eric Tartour, Ludger Johannes, Stephane Oudard, Jacques Medioni, Luis CS Ferreira, Craig Sibley, Sylvie Godefroy, Yu Chun Lone, Nathalie Merillon, Alain Gey, Estelle Dransart, Mariana O. Diniz, Thi Tran
Supplementary Fig 1 : Establishment of a Her2-HLA-A2 B16 tumor model in HLA-A2 TG mice. Supplementary Fig 2 : STxB-E75 combined with GM-CSF and CpG induced potent anti-Her2 CD8+T cells. Supplementary Fig 3 : Presence of intratumoral anti-E75 CD8+T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fa6b073a8278eaa7e59dc01c19a89a1
https://doi.org/10.1158/1078-0432.22463196.v1
https://doi.org/10.1158/1078-0432.22463196.v1